Smartphone-based devices and applications (SBDAs) with cost effectiveness and remote
sensing are the most promising and effective means of delivering mobile healthcare …

Prostate specific antigen (PSA) remains the most used biomarker in the management of
early prostate cancer (PCa), in spite of the problems related to false positive results and …

Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because
it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for …

Prostate cancer is one of the most common cancers affecting men with> 1,100,000 new
cases and 300,000 deaths worldwide each year. The disease is more common among older …

Genome-wide association studies (GWAS) have been successful in deciphering the genetic
component of predisposition to many human complex diseases including prostate cancer …

The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication
have revolutionized the diagnosis and management of the disease. Current clinical practice …

Background Admixture between early modern humans and Neandertals approximately
50,000–60,000 years ago has resulted in 1.5–4% Neandertal ancestry in the genomes of …

Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression.
The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous …

Prostate cancer (PC) has the highest degree of genetic transmission of any form of
malignancy. In some families, the hereditary pattern is so strong as to mimic an autosomal …

Background Several recent studies have provided evidence that polymorphisms in the
telomerase reverse transcriptase (TERT) gene sequence are associated with cancer …